Clinical Trial

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP inhibitors . In vitro evidence suggests that low-carbohydrate culture conditions may restore PARP inhibitor sensitivity in HRD-negative tumor cells. This study aims to validate the survival benefits of fluzoparib combined with bevacizumab in HRD-positive ovarian cancer patients during first-line maintenance therapy and explore the efficacy of fluzoparib combined with a dietary intervention in HRD-negative populations.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-24.
Status change: Not Yet Recruiting → Recruiting 2025-06-17
Trial Details
NCT Number NCT06954584
Lead Sponsor Tongji Hospital
Conditions Ovarian Cancer
Enrollment 424 participants
Start Date 2025-05-27
Primary Completion 2030-05-01 (estimated)
Study Completion 2032-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-24